Today’s AI Top Pick: TMDX

TransMedics (TMDX) is the cleanest setup where fundamentals and tape both agree. Fundamentally it clears the screen with room to spare: PE 16.17, fwdPe 21.45, ROE 45.22, profit margin 27.04%, sales YoY +30.24%, EPS next year +70.83%, recom 1.64, targetUpsidePct 65% — a rare 'real business at a reset price' after a -43.5% 1Y drawdown. Fundamental score 6.75 is among the highest in the pool and, unlike PSIX (7.5), it isn't paired with a -60% weekly forecast. The tape confirms across every horizon with no ugly outlier. Bullish_prob = 1.0 and near_term_bullish = 1.0. Forecasts stack cleanly: 1h fc_long +59.24%, 4h fc_mid +65.97% / fc_long +135.35%, 1d fc_short +52.65% / fc_mid +68.5% / fc_long +57.04%, and even the 1wk stays positive (+32.32% / +30.18%). Crucially, the entry is NOT extended: pos_in_21bar_range is 32.5% on the daily and only 7.3% on the weekly, with dd_from_21bar_high of -10.6% (1d) and -52.35% (1wk). You are buying near the low of a wide base with all forecast horizons pointing up — the opposite of chasing. News is a mild net-neutral rather than a landmine: Evercore ISI trimmed the target to $90 but kept Outperform, and Motley Fool ran a long-term bull piece. There is no dilution, no going-concern flag, no short-seller report — the kinds of headlines that torpedo names like AIM, DFDV, ASST, or CTXR. That matters because several tape-strong names in this pool are undermined by narrative (CELH price target cut + tape-heavy selling, CWH declining sales/widening losses, QXO under regulatory scrutiny, KULR extending ATM offering). Why today, not later: the 1h and 4h forecasts already show short-horizon positive drift (+0.51% / +4.32%), so waiting for a deeper pullback risks missing the mid-term move. With the stock only ~7% above its 21-week low and a clean multi-TF stack, entering now offers an attractive risk/reward: define risk under the recent low and let the -43% 1Y reversal play out toward the $90 analyst target.